Llovet M, Josep RK, Kelley A, Villanueva AG, Singal E, Pikarsky S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6. https://doi.org/10.1038/s41572-020-00240-3.
Zhang H, Zhang W, Jiang L, Chen Y. Recent advances in systemic therapy for hepatocellular carcinoma. Biomarker Res. 2022;10:3. https://doi.org/10.1186/s40364-021-00350-4.
Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol. 2015;7:1632–51. https://doi.org/10.4254/wjh.v7.i12.1632.
Article PubMed PubMed Central Google Scholar
Sarveazad A, Agah S, Babahajian A, Amini N, Bahardoust M. Predictors of 5 year survival rate in hepatocellular carcinoma patients. J Res Med Sci. 2019;24:86. https://doi.org/10.4103/jrms.JRMS_1017_18.
Article PubMed PubMed Central Google Scholar
Targe M, Yasam VR, Nagarkar R. Hepatocellular carcinoma with uncommon sites of metastasis: a rare case report. Egypt J Radiol Nucl Med. 2021;52:228. https://doi.org/10.1186/s43055-021-00612-z.
Tiwari N, Alexander G, Marianthi T, Gerhard C. EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol. 2012;22:194–207. https://doi.org/10.1016/j.semcancer.2012.02.013.
Article CAS PubMed Google Scholar
Dongre A, Weinberg AR. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20:69–84. https://doi.org/10.1038/s41580-018-0080-4.
Article CAS PubMed Google Scholar
Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022;15:1–129. https://doi.org/10.1186/s13045-022-01347-8.
Yin Q, Zheng M, Luo Q, Jiang D, Zhang H, Chen C. YB-1 as an oncoprotein: functions, regulation, post-translational modifications, and targeted therapy. Cells. 2022;11:1217. https://doi.org/10.3390/cells11071217.
Article CAS PubMed PubMed Central Google Scholar
Valentina E, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell. 2009;15:402–15. https://doi.org/10.1016/j.ccr.2009.03.017.
Xiumei L, Chen D, Chen H, Wang W, Liu Y, Wang Y, et al. YB1 regulates miR-205/200b-ZEB1 axis by inhibiting microRNA maturation in hepatocellular carcinoma. Cancer Commun. 2021;41:576–95. https://doi.org/10.1002/cac2.12164.
Wang X, Li Y, Dai H, Xu C. Crystal structure of the WD40 domain of human PLRG1. Biochem Biophys Res Commun. 2021;534:474–7. https://doi.org/10.1016/j.bbrc.2020.11.057.
Sittinan C, Sträßer K. Splicing and Beyond: The many faces of the Prp19 complex. BBA-Mol Cell Res. 2013;1833:2126–34. https://doi.org/10.1016/j.bbamcr.2013.05.023.
Yin J, Zhang YA, Liu TT, Zhu JM, Shen XZ. DNA damage induces down-regulation of Prp19 via impairing Prp19 stability in hepatocellular carcinoma cells. PLoS ONE. 2014;9: e89976. https://doi.org/10.1371/journal.pone.0089976.
Article CAS PubMed PubMed Central Google Scholar
Zhang Z, Mao W, Wang L, Liu M, Zhang W, Wu Y, et al. Depletion of CDC5L inhibits bladder cancer tumorigenesis. J Cancer. 2020;11:353–63. https://doi.org/10.7150/jca.32850.
Article CAS PubMed PubMed Central Google Scholar
Huang R, Xue R, Qu D, Yin J, Shen XZ. Prp19 Arrests Cell Cycle via Cdc5L in hepatocellular carcinoma cells. Int J Mol Sci. 2017;18:778. https://doi.org/10.3390/ijms18040778.
Article CAS PubMed PubMed Central Google Scholar
Benjamin AB, Zhou X, Isaac O, Zhao H, Song Y, Chi X, et al. (2014) PRP19 upregulation inhibits cell proliferation in lung adenocarcinomas by p21-mediated induction of cell cycle arrest. Biomed Pharmacother. 2014;68:463–70. https://doi.org/10.1016/j.biopha.2014.03.006.
Article CAS PubMed Google Scholar
Yin J, Wang L, Zhu JM, Yu Q, Xue RY, Fang Y, et al. Prp19 facilitates invasion of hepatocellular carcinoma via p38 mitogen-activated protein kinase/twist1 pathway. Oncotarget. 2016;7:21939–51. https://doi.org/10.18632/oncotarget.7877.
Article PubMed PubMed Central Google Scholar
Choi H, Kang M, Lee KH, Kim YS. Elevated level of PLRG1 is critical for the proliferation and maintenance of genome stability of tumor cells. BMB Rep. 2023;56:612–7. https://doi.org/10.5483/BMBRep.2023-0162.
Article CAS PubMed PubMed Central Google Scholar
Zhen L, Ye Y, Liu Y, Liu Y, Chen H, Shen M, et al. RNA helicase DHX37 facilitates liver cancer progression by cooperating with PLRG1 to drive superenhancer-mediated transcription of Cyclin D1. Cancer Res. 2022;82:1937–52. https://doi.org/10.1158/0008-5472.CAN-21-3038.
Shuyan L, Wang T, Shi Y, Bai L, Wang S, Guo D, et al. USP42 Drives nuclear speckle mRNA splicing via directing dynamic phase separation to promote tumorigenesis. Cell Death Differ. 2021;28:2482–98. https://doi.org/10.1038/s41418-021-00763-6.
Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47:556–60. https://doi.org/10.1093/nar/gkz430.
Llères D, Denegri M, Biggiogera M, Ajuh P, Lamond AI. Direct interaction between HnRNP-M and CDC5L/PLRG1 proteins affects alternative splice site choice. EMBO Rep. 2010;11:445–51. https://doi.org/10.1038/embor.2010.64.
Article CAS PubMed PubMed Central Google Scholar
Zhang Y, Qian J, Gu C, Yang Y. Alternative splicing and cancer: a systematic review. Signal Transduct Target Ther. 2021;6:78. https://doi.org/10.1038/s41392-021-00486-7.
Article CAS PubMed PubMed Central Google Scholar
Dvinge H, Kim E, Abdel-Wahab O, Bradley RK. RNA splicing factors as oncoproteins and tumour suppressors. Nat Rev Cancer. 2016;16:413–30. https://doi.org/10.1038/nrc.2016.51.
Article CAS PubMed PubMed Central Google Scholar
Anczukow O, Krainer AR. Splicing-factor alterations in cancers. RNA. 2016;22:1285–301. https://doi.org/10.1261/rna.057919.116.
Article CAS PubMed PubMed Central Google Scholar
Du JX, Luo YH, Zhang SJ, Wang B, Chen C, Zhu GQ, et al. Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1. J Exp Clin Cancer Res. 2021;40:171. https://doi.org/10.1186/s13046-021-01978-8.
Article CAS PubMed PubMed Central Google Scholar
Stickeler E, Fraser SD, Honig A, Chen AL, Berget SM, Cooper TA. The RNA binding protein YB-1 binds A/C-rich exon enhancers and stimulates splicing of the CD44 alternative exon v4. EMBO J. 2001;20:3821–30. https://doi.org/10.1093/emboj/20.14.3821.
Article CAS PubMed PubMed Central Google Scholar
Guo T, Zhao S, Wang P, Xue X, Zhang Y, Yang M, et al. YB-1 regulates tumor growth by promoting MACC1/c-Met pathway in human lung adenocarcinoma. Oncotarget. 2017;8:48110–25. https://doi.org/10.18632/oncotarget.18262.
留言 (0)